Skip to content

Artificial Intelligence in Diagnosis of DFNA9

Positive Predictive Value of Machine Learning Tools (Audiogene v4.0) for Diagnosing DFNA9 in a Large Series of p.Pro51Ser Variant Carriers in COCH.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04331015
Acronym
DFNA9
Enrollment
111
Registered
2020-04-02
Start date
2020-02-01
Completion date
2020-03-28
Last updated
2020-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DFNA9, Sensorineural Hearing Loss

Keywords

COCH, DFNA9, sensorineural hearing loss

Brief summary

To study the positive predictive value of Audiogene v.4.0 open source online machine learning tool in accurately predicting DFNA9 (DeaFNess autosomal dominant ninth) as top 3 gene loci in a large series of genetically confirmed c.151C\>T,p.Pro51Ser (p.P51S) variant carriers in COCH (coagulation factor C Homology).

Detailed description

DFNA9 is an autosomal dominant hereditary adult-onset and progressive sensorineural hearing loss which is associated wit vestibular deterioration. Today, artificial intelligence plays an increasing role in diagnosis of Mendelian hearing losses and in fitting of cochlear implants. An application of this kind is the open source program, Audiogene v4.0, which was elaborated by the Center for Bioinformatics and Computational Biology, University of Iowa City, Iowa, USA. The shape of the audiogram (audioprofile) is easily recognizable in many autosomal dominantly inherited hearing losses. Machine learning based software tools, such as Audiogene v4.0, which was originally developed for prioritizing loci for the Sanger sequencing, could help the clinicians in early diagnosis of DFNA9. This tool only need subjects' age and hearing thresholds (decibel hearing loss (dB HL)) at frequency range of 0.125 - 8 kHz (kiloHerz), left, right or binaural average in order to predict top 3 gene loci according to the data entered in the program. Goal: to use auditory data of a large series of genetically confirmed p.P51S variant carriers causing DFNA9, which were previously collected for the genotype-phenotype correlation study which terminated recently. All individual left and right sided hearing thresholds (ranging from 0.125 to 8kHz, with the exception of 1.5 kHz) as well as binaural averaged thresholds were run through Audiogene v4.0. Descriptive statistics were assessed and statistical analysis was carried out to check for possible differences between age or hearing thresholds between the carrier group with accurate prediction against the carrier group with inaccurate prediction.

Interventions

DIAGNOSTIC_TESTPure tone audiometry

pure tone audiometry

Sponsors

Jessa Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* at least 18 years * genetically confirmed c.151 C\>T, p.Pro51Ser variant carrier in COCH gene * not contra-indication for audiometric testing

Exclusion criteria

* \<18 years * no carrier status for c.151C\>T, p.Pro51Ser * no auditory data available

Design outcomes

Primary

MeasureTime frameDescription
hearing threshold1 houraudiometry (pure tone) decibel hearing level (dB HL) left, right ear , binaural average
age1 houryears, age at time of audiometry
prediction gene locus1 hourtop 3 gene loci as predicted by Audiogene v4.0 machine learning tool

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026